Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most impor...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2020/9235638 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560326407618560 |
|---|---|
| author | Massimo Ralli Andrea Botticelli Irene Claudia Visconti Diletta Angeletti Marco Fiore Paolo Marchetti Alessandro Lambiase Marco de Vincentiis Antonio Greco |
| author_facet | Massimo Ralli Andrea Botticelli Irene Claudia Visconti Diletta Angeletti Marco Fiore Paolo Marchetti Alessandro Lambiase Marco de Vincentiis Antonio Greco |
| author_sort | Massimo Ralli |
| collection | DOAJ |
| description | Melanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy. Immunotherapy is associated to a panel of dysimmune toxicities called immune-related adverse events that can affect one or more organs and may limit its use. Future directions in the treatment of metastatic melanoma include immunotherapy with anti-PD1 antibodies or targeted therapy with BRAF and MEK inhibitors. |
| format | Article |
| id | doaj-art-8a4903e048794c668230a7c29b707433 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-8a4903e048794c668230a7c29b7074332025-02-03T01:27:54ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/92356389235638Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future DirectionsMassimo Ralli0Andrea Botticelli1Irene Claudia Visconti2Diletta Angeletti3Marco Fiore4Paolo Marchetti5Alessandro Lambiase6Marco de Vincentiis7Antonio Greco8Department of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155-00161 Rome, ItalyDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Viale del Policlinico 155-00161 Rome, ItalyDepartment of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155-00161 Rome, ItalyDepartment of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155-00161 Rome, ItalyInstitute of Cell Biology and Neurobiology, IBCN-CNR, Rome, ItalyDepartment of Clinical and Molecular Medicine, Sapienza University of Rome, Viale del Policlinico 155-00161 Rome, ItalyDepartment of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155-00161 Rome, ItalyDepartment of Oral and Maxillofacial Sciences, Sapienza University of Rome, Viale del Policlinico 155-00161 Rome, ItalyDepartment of Sense Organs, Sapienza University of Rome, Viale del Policlinico 155-00161 Rome, ItalyMelanoma is one of the most immunologic malignancies based on its higher prevalence in immune-compromised patients, the evidence of brisk lymphocytic infiltrates in both primary tumors and metastases, the documented recognition of melanoma antigens by tumor-infiltrating T lymphocytes and, most important, evidence that melanoma responds to immunotherapy. The use of immunotherapy in the treatment of metastatic melanoma is a relatively late discovery for this malignancy. Recent studies have shown a significantly higher success rate with combination of immunotherapy and chemotherapy, radiotherapy, or targeted molecular therapy. Immunotherapy is associated to a panel of dysimmune toxicities called immune-related adverse events that can affect one or more organs and may limit its use. Future directions in the treatment of metastatic melanoma include immunotherapy with anti-PD1 antibodies or targeted therapy with BRAF and MEK inhibitors.http://dx.doi.org/10.1155/2020/9235638 |
| spellingShingle | Massimo Ralli Andrea Botticelli Irene Claudia Visconti Diletta Angeletti Marco Fiore Paolo Marchetti Alessandro Lambiase Marco de Vincentiis Antonio Greco Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions Journal of Immunology Research |
| title | Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions |
| title_full | Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions |
| title_fullStr | Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions |
| title_full_unstemmed | Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions |
| title_short | Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions |
| title_sort | immunotherapy in the treatment of metastatic melanoma current knowledge and future directions |
| url | http://dx.doi.org/10.1155/2020/9235638 |
| work_keys_str_mv | AT massimoralli immunotherapyinthetreatmentofmetastaticmelanomacurrentknowledgeandfuturedirections AT andreabotticelli immunotherapyinthetreatmentofmetastaticmelanomacurrentknowledgeandfuturedirections AT ireneclaudiavisconti immunotherapyinthetreatmentofmetastaticmelanomacurrentknowledgeandfuturedirections AT dilettaangeletti immunotherapyinthetreatmentofmetastaticmelanomacurrentknowledgeandfuturedirections AT marcofiore immunotherapyinthetreatmentofmetastaticmelanomacurrentknowledgeandfuturedirections AT paolomarchetti immunotherapyinthetreatmentofmetastaticmelanomacurrentknowledgeandfuturedirections AT alessandrolambiase immunotherapyinthetreatmentofmetastaticmelanomacurrentknowledgeandfuturedirections AT marcodevincentiis immunotherapyinthetreatmentofmetastaticmelanomacurrentknowledgeandfuturedirections AT antoniogreco immunotherapyinthetreatmentofmetastaticmelanomacurrentknowledgeandfuturedirections |